Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2024 Jun;130(12):1916-1920.
doi: 10.1038/s41416-024-02685-9. Epub 2024 Apr 24.

Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

Daire Hanna  1   2 , Sophie Merrick  3 , Aruni Ghose  4 , Michael John Devlin  4 , Dorothy D Yang  5 , Edward Phillips  5 , Alicia Okines  5 , Neha Chopra  6 , Elisavet Papadimatraki  3 , Kirsty Ross  7 , Iain Macpherson  7 , Zhuang Y Boh  8 , Caroline O Michie  8 , Angela Swampillai  9 , Sunnia Gupta  9 , Tim Robinson  10 , Lewis Germain  11 , Chris Twelves  11 , Charlotte Atkinson  12 , Apostolos Konstantis  3   13 , Pippa Riddle  14 , Nicola Cresti  15 , Jay D Naik  16 , Annabel Borley  17 , Amy Guppy  18 , Peter Schmid  4 , Melissa Phillips  4
Affiliations
Multicenter Study

Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom

Daire Hanna et al. Br J Cancer. 2024 Jun.

Abstract

Background: Treatment options for pre-treated patients with metastatic triple-negative breast cancer (mTNBC) remain limited. This is the first study to assess the real-world safety and efficacy of sacituzumab govitecan (SG) in the UK.

Methods: Data was retrospectively collected from 16 tertiary UK cancer centres. Pts had a diagnosis of mTNBC, received at least two prior lines of treatment (with at least one being in the metastatic setting) and received at least one dose of SG.

Results: 132 pts were included. Median age was 56 years (28-91). All patients were ECOG performance status (PS) 0-3 (PS0; 39, PS1; 76, PS2; 16, PS3;1). 75% (99/132) of pts had visceral metastases including 18% (24/132) of pts with CNS disease. Median PFS (mPFS) was 5.2 months (95% CI 4.5-6.6) with a median OS (mOS) of 8.7 months (95% CI 6.8-NA). The most common adverse events (AEs) were fatigue (all grade; 82%, G3/4; 14%), neutropenia (all grade; 55%, G3/4; 29%), diarrhoea (all grade; 58%, G3/4, 15%), and nausea (all grade; 38%, G3/4; 3%). SG dose reduction was required in 54% of pts.

Conclusion: This study supports significant anti-tumour activity in heavily pre-treated pts with mTNBC. Toxicity data aligns with clinical trial experience.

PubMed Disclaimer

Conflict of interest statement

Dr Daire Hanna: Honorarium from Gilead. Dr Melissa Phillips: Honorarium from Gilead, Esai, Novartis, Roche, Pfizer, MSD. Dr Caroline Michie: Speaker fees or advisory board funding from Gilead, AstraZeneca, Eisai, Eli Lilly, Novartis, Pfizer, Roche, Exact Sciences and Seagen; conference travel support from Novartis and Roche. Dr Tim Robinson: Funding for conference attendance from MSD; funding for educational workshops from Daiichi-Sanko; supported by an NIHR Development and Skills Enhancement Award (NIHR 302363). Dr Iain MacPherson: Consulting fees from Astra Zeneca, Eli Lilly, Gilead, Novartis, Pfizer, Roche, and Stemline Therapeutics. Dr Neha Chopra: conference grant from Gilead; presentation fees from Pfizer. Dr Amy Guppy: conference grant from Gilead; funding for educational workshops from Novartis and Exact Science. Dr Jay Naik: non-promotional educational support (workshops/facilitation) from AstraZeneca and Daiichi. All other authors declare no conflicts of interest.

Figures

Fig. 1
Fig. 1. Overall survival of study population.
a Kaplan–Meier curve of the progression-free survival of study population. b Kaplan–Meier curve of the overall survival of study population.
Fig. 2
Fig. 2. Subgroup analysis of survival by ECOG performance status.
a Kaplan–Meier curves of the overall survival of ECOG PS 0, ECOG PS 1 and ECOG PS 2 or 3 patients. b Kaplan–Meier curves of the progression-free survival of ECOG PS 0, ECOG PS 1 and ECOG PS 2 or 3 patients.
Fig. 3
Fig. 3. Subgroup analysis of survival by number of treatment lines.
a Kaplan–Meier curves of the overall survival of patients who received 1–2 and 3 or more prior lines of treatment in the metastatic setting. b Kaplan–Meier curves of the progression-free survival of patients who received 1–2 and 3 or more prior lines of treatment in the metastatic setting.
See this image and copyright information in PMC

References

    1. Breast cancer statistics | Cancer Research UK [Internet]. [cited 2023 Jun 5]. Available from: https://www.cancerresearchuk.org/health-professional/cancer-statistics/s....
    1. Diana, Franzese A, Centonze E, Carlino S, Corte F, Della CM, et al. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs. Curr Oncol Rep. 2018;20:76. doi: 10.1007/s11912-018-0726-6. - DOI - PubMed
    1. Gobbini E, Ezzalfani M, Dieras V, Bachelot T, Brain E, Debled M, et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer. 2018;96:17–24. doi: 10.1016/j.ejca.2018.03.015. - DOI - PubMed
    1. Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674. doi: 10.1136/bmj-2022-071674. - DOI - PubMed
    1. O'Reilly D, Sendi MA, Kelly CM. Overview of recent advances in metastatic triple negative breast cancer. World J Clin Oncol. 2021;12:164–82. doi: 10.5306/wjco.v12.i3.164. - DOI - PMC - PubMed

Publication types

MeSH terms